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Abstract
We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and
serum heavy-light chains (sHLC) in patients withmultiplemyeloma treated according to the
GEM2005MENOS65, GEM2005MAS65, andGEM2010MAS65PETHEMA/GEM phase III
clinical trials. Serum samples collected at diagnosiswere retrospectively analyzed for sFLC (n =
623) and sHLC (n = 183). After induction or autologous transplantation, 309 and 89 samples
respectively were available for sFLC and sHLC assays. At diagnosis, a highly abnormal (HA)
sFLC ratio (sFLCr) (<0.03 or >32) was not associatedwith higher risk of progression. After ther-
apy, persistence of involved-sFLC levels >100mg/L impliedworse survival (overall survival
[OS], P = 0.03; progression-free survival [PFS], P = 0.007). Among patients that achieved a
complete response, sFLCr normalization did not necessarily indicate a higher quality response.
We conducted sHLC investigations for IgG and IgAMM. Absolute sHLC valueswere correlated
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Investigación Cooperativa en Cáncer (RTICC) of the
Instituto de Salud Carlos III (Ministry of Economy,
withmonoclonal protein levelsmeasuredwith serum protein electrophoresis. At diagnosis, HA-
sHLCrs (<0.29 or >73) showed a higher risk of progression (P = 0.006). Additionally, involved-
sHLC levels>5 g/L after treatment were associatedwith shorter survival (OS,P = 0.001; PFS,P =
0.018). The HA-sHLCr could have prognostic value at diagnosis; absolute values of involved-
sFLC >100mg/L and involved-sHLC>5 g/L could have prognostic value after treatment.
Introduction
The immunoassay for quantifying free immunoglobin light chains in serum (sFLC) has been a
valuable tool for diagnosing and monitoring light-chain multiple myeloma (MM) [1], amyloid
light-chain amyloidosis, [2], and monoclonal gammopathies of undetermined significance
(MGUS) [3,4]. Moreover, the recently developed assays for quantifying specific immunoglobin
heavy-light chain complexes in serum (sHLC) have enabled accurate measurements of the dif-
ferent types of light chains (termed κ and λ) coupled with a specific heavy chain (i.e., IgA, IgG,
or IgM) in intact immunoglobulins. Thus, the ratios of heavy-light chain-κ to heavy-light
chain-λ can be determined (e.g., the IgG-κ:IgG-λ ratio). The latter assay has made it possible
to measure isotype-specific suppression of the sHLC pair that is not involved with the disease,
such as the suppression of IgA-λ in a patient with IgA-κ type MM [5,6].
The sFLC assays complement the classic assays of serum protein electrophoresis (sPE) and
immunofixation, which increases the diagnostic sensitivity of serum protein studies in MM
[4]. In addition to its diagnostic utility [3], an abnormal sFLC ratio (sFLCr) is a risk factor for
progression from MGUS, smoldering myeloma, or solitary plasmacytoma to symptomatic
MM. However, the prognostic role of sFLC in symptomatic MM remains unclear
[1,4,7,8,9,10,11]. Some studies have reported a relationship between baseline levels of the
involved-sFLC level or the sFLCr and the disease burden; however, other studies have not
found any relationship [1,4,7,9,10,11].
The normalization of sFLCr has been incorporated into the consensus definition of a strin-
gent complete response (CR) [12,13,14]. However, a previous analysis conducted by our group
failed to demonstrate a prognostic role for normal sFLCrs in the CR [15]. The short half-lives
of κ and λ FLCs may make them a reliable indicator of the response to treatment, but their
clinical utility in this context remains under investigation. Moreover, sFLCs are likely to be
more useful than conventional methods for diagnosing light-chain MM [16].
A recent report [17] showed that quantification with the IgA sHLC assay was more accurate
than either an M-protein quantification with sPE or a total IgA quantification with nephelom-
etry. Thus, the sHLC assay could provide a solution to some issues associated with co-migra-
tion in electrophoresis, particularly in cases of oligosecretory MM. However, only a few
published reports [18,19] and several small case series have addressed the use of sHLC analyses
for evaluating patients with MM.
In the present study, we extended our previous series [15] to investigate the utility and
prognostic impact of the sFLCr and the sHLCr. We measured the levels of involved-sFLC and
involved-sHLC at diagnosis and after therapy in patients with MM treated in the PETHEMA/
GEM phase III clinical trials.
Patients andmethods
Patients and treatment
All patients were included and treated according to the protocols implemented in three
PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatı́as Malignas/
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Grupo Español de Mieloma) phase III clinical trials [20,21,22]. In brief, in the GEM2005ME-
NOS65 trial (NCT00461747), 390 patients (130 per arm) were randomly assigned to receive
one of the following induction therapies: (arm 1: VCMP/VBAD/B) vincristine, BCNU, mel-
phalan, cyclophosphamide, prednisone (VCMP)/ vincristine, BCNU, doxorubicin (Adriamy-
cin1), and dexamethasone (VBAD), followed by two courses of bortezomib (B); (arm 2: TD)
thalidomide and dexamethasone or (arm 3: VTD) bortezomib, thalidomide, and dexametha-
sone. All patients were scheduled to undergo autologous stem cell transplantation with high-
dose melphalan, followed by maintenance therapy with interferon alpha-2b, thalidomide, or
thalidomide plus one cycle of bortezomib, every 3 months for up to 3 years. In the GEM2005-
MAS65 trial (NCT00443235), 260 patients were randomly assigned to receive six cycles of one
of the following induction therapies: (arm 1: VMP) bortezomib, melphalan, and prednisone or
(arm 2: VTP) bortezomib, thalidomide, and prednisone. This treatment was followed by main-
tenance with bortezomib and thalidomide or bortezomib and prednisone for up to 3 years. In
the GEM2010MAS65 trial (NCT01237249), 260 patients >65 years old were randomly
assigned to receive 18 cycles of the following induction therapies: (arm 1) nine cycles of VMP,
followed by nine cycles of lenalidomide and dexamethasone or (arm 2) alternating cycles of
VMP and lenalidomide+dexamethasone [22]. All patient serum samples were collected after
obtaining informed consent, and the study was conducted in accordance with the local ethics
committee (Hospital Universitario 12 de Octubre ethics committee) and the Helsinki
Declaration.
Protein analysis
The sPE assays were conducted with agarose gel electrophoresis (REP; Helena Laboratories,
Beaumont, TX, USA) and/or capillary electrophoresis (V8; Helena Biosciences Europe, Gates-
head, UK). Serum immunofixation assays were performed to evaluate γ, α, μ, κ, and λ immu-
noglobulin chains (Hydrasys and Hydragel; Sebia, Lisses, France, and/or SAS-3 and SAS-4,
Helena Biosciences Europe).
sFLC and sHLC analysis
We performed the sFLC assay (FREELITE1; The Binding Site, Birmingham, UK) on an auto-
mated nephelometer (BNII; Dade Behring, Marburg, Germany) or a turbidimeter (SPA-PLUS;
The Binding Site, Birmingham, UK), with similar results. We quantified IgG-κ, IgG-λ, IgA-κ,
and IgA-λ with Hevylite™ reagents provided by the manufacturer in a turbidimeter (SPA--
PLUS; The Binding Site). For the sHLC assay, we derived reference ranges for the IgG and IgA
sHLC proteins from 30 healthy serum donors that were 50–65 years old and equally balanced
for sex; this analysis yielded similar ranges as previously described by other authors (Table 1)
[5,6,18].
Statistical analysis
Survival was analyzed with the Kaplan–Meier method, and statistical significance was tested
with the two-sided log-rank test. Progression-free survival (PFS) was measured from the first
day of random assignment to the day that disease progression was detected or the day of death
from any cause. Overall survival (OS) was measured from the day of first random assignment
to the day of death from any cause. A multivariate Cox proportional hazards model (stepwise
regression) was developed to explore independent effects on survival. Variables were retained
in the model when levels of significance were P<0.05. All statistical analyses were performed
with SPSS software, version 20.0 (SPSS, Chicago, IL, USA).
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Results
Of 819 included patients, serum samples for sFLC and sHLC analyses were available at the
time of diagnosis in 623 and 183 cases, respectively. After induction (GEM2005MAS65 and
GEM2010MAS65) or after autologous transplantation (GEM2005MENOS65), samples were
available in 309 cases for sFLC and 89 for sHLC (flow chart, Fig 1). All patients included in the
sHLC analysis had either IgG or IgA MM. For the entire series, the median follow-up time was
75 months. S1 Table shows the patient baseline demographics and disease characteristics.
Prognostic impact of sFLC
sFLCr at diagnosis: At diagnosis, 92% of the sFLCr values were abnormal. However, when
these abnormal values were used to define threshold values, even the highest ratio had no prog-
nostic influence (PFS, P = 0.082, Fig 2A; OS, P = 0.404, Figure A in S1 Fig). Similarly, absolute
involved-sFLC values100 mg/L (or any arbitrary cut-off) measured at diagnosis were not
associated with the differences in outcome observed in groups defined by the cutoff.
sFLCr in post-treatment response assessments: The prognostic impact of sFLCr normaliza-
tion is shown in Fig 2B. We observed better survival among patients with normal sFLCr com-
pared to those with abnormal sFLCr values (median PFS, 53 vs. 42 months, P = 0.016; median
OS, not reached (NR) vs. 80 months, P = 0.025, Figure B in S1 Fig). The relationships between
normal/abnormal sFLCr and the degree of response are shown in Table 2. As expected, we
found that normalization of the sFLCr was associated with a higher degree of response. How-
ever, when we analyzed the impact of sFLCr normalization on survival among the 130 patients
that achieved CR after induction, we found no significant survival differences (OS, P = 0.137;
PFS, P = 0.359) between patients with normal (0.26–1.65) vs. abnormal sFLCr (Fig 2C;
Figure C in S1 Fig).
Next, we explored the prognostic influence of a persistently abnormal value of involved-
sFLC after treatment. We found that, when the absolute value of involved-FLCs was100mg/
L, it could identify patients at an increased risk of progression; a receiver operating curve
(ROC) analysis showed an area under the curve (AUC) of 0.82, a sensitivity of 60%, and a spec-
ificity of 89% (P <0.0001)].When we applied these criteria (100 or<100 mg/L involved-
Table 1. Reference ranges for serum IgG and IgA heavy-light chain concentrations, based on samples from
healthy individuals (controls) and previously published data.
Source for IgG controls IgG-K (g/L) IgG-λ (g/L) IgG-K/IgG-λ (95% RI)
Controls (n = 30) 5.45–6.5 2.65–3.25 1.89–2.33
95% RI (min–max) (3.16–8.18) (1.75–5.28) (1.02–3.22)
IgG HLC product inserts: SPAPLUS 3.84–12.07 1.91–6.74 1.12–3.21
IgG HLC product inserts: BNII 4.03–9.78 1.97–5.71 0.98–2.75
Katzmann et al. [5,6] 4.34–10.80 1.77–5.31 1.30–3. 70 [5]/1.17–3.61 [6]
Source for IgA controls IgA-K (g/L) IgA-λ (g/L) IgA-K/IgA-λ (95% RI)
Controls (n = 30) 1.16–1.50 0.76–0.94 1.43–1.70
RI 95% (min–max) (0.61–2.43) (0.42–1.42) (0.94–2.58)
IgA HLC product inserts: SPAPLUS 0.57–2.08 0.44–2.04 0.78–1.94
IgA HLC product inserts: BNII 0.48–2.82 0.36–1.98 0.80–2.04
Katzmann et al.[5,6] 0.53–2.62 0.38–1.81 0.70–2.20 [5,6]
 (minimum–maximum)
RI, reference interval; HLC, heavy-light chain; SPAplus: turbidimeter purchased from The Binding Site (Birmingham,
UK); BNII: nephelometer, purchased from Dade Behring (Marburg, Germany)
https://doi.org/10.1371/journal.pone.0203392.t001
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Fig 1. Flow chart: Patient inclusion and analyzed samples.
https://doi.org/10.1371/journal.pone.0203392.g001
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sFLC) to our data, we found that, after treatment, an absolute value of involved-sFLC100
mg/L was associated with worse survival (median OS, NR vs. 58 months, P = 0.03; Figure D in
S1 Fig; and median PFS, 50 vs. 33 months, P = 0.007; Fig 2D). When we analyzed only patients
with a partial response, we found that an absolute value of involved-sFLC100 mg/L after
treatment was also associated with a higher risk of progression (median OS, NR vs. 79 months,
P = 0.158; median PFS, 43 vs. 24 months, P = 0.015).
Prognostic impact of sHLC
sHLCr at diagnosis: At diagnosis, the sHLCr was abnormal in 98% of patients. The level of IgG
or IgA monoclonal protein (MP), determined with a sHLC analysis, showed a high linear cor-
relation with the absolute values of MP assessed with sPE (P<0.001; Pearson’s r = 0.663) (Fig
3). This correlation was also confirmed after treatment (P<0.01; Pearson’s r = 0.692).
We observed that absolute values of involved-sHLC relate to the tumor burden (Fig 4A),
and we noted that HA-sHLCr values (<0.29 or >73) at the time of diagnosis were associated
Fig 2. Progression-free survival (PFS) relationships to serum free light chain (sFLC) evaluations. (A) PFS among patients with “highly abnormal” sFLC ratios (<0.03
or>32, red lines, median PFS: 38 mo) compared to those with normal sFLC ratios (0.03–32, blue lines, median PFS: 29 mo). (B) PFS among patients with normal (blue,
median PFS: 53 mo) or abnormal (red, median PFS: 42 mo) sFLC ratios after treatment, regardless of the response achieved. (C) PFS among patients that achieved
complete response (CR) with normal (blue, median PFS: 60 mo) or abnormal (red, median PFS: 59 mo) sFLC ratios. (D) PFS among patients with absolute involved-
sFLC levels<100 mg/L (blue, median PFS: 50 mo) or100 mg/L (red, median PFS: 33 mo).
https://doi.org/10.1371/journal.pone.0203392.g002
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with a shorter PFS, (P = 0.009; Fig 4B). This finding was confirmed by multivariate analysis, in
which an increased risk of progression was associated with the following factors: the HA-
sHLCr (odds ratio [OR] 1.78, 95% confidence interval [CI]: 1.14–2.78; P = 0.01), age: (OR
1.04, 95% CI: 1.01–1.06; P = 0.003); LDH (OR 0.4, 95%CI: 0.26–0.94; P = 0.03), and a high- vs.
low-risk FISH result (OR 1.75, 95%CI: 1.11–2.74; P = 0.02; S2 Table). Although not statistically
significant, we noted a trend towards an association between HA involved-sHLC values and a
shorter PFS (P = 0.07).
Finally, the suppression of the uninvolved-sHLC pair was not associated with prognosis in
our series (OS, P = 0.89; PFS, P = 0.57).
sHLCr in post-treatment response assessments: After treatment, we found no statistically sig-
nificant association between sHLCr normalization and survival (OS, P = 0.841; PFS,
P = 0.402).
Next, we explored the prognostic value of involved-sHLC that were persistently abnormal
after treatment. A ROC curve analysis (AUC 0.859; sensitivity, 100%; specificity, 70%;
P = 0.002) suggested that involved-sHLC values <5 g/L would be the best cut-off for identify-
ing patients that responded to treatment. Absolute involved-sHLC values5 g/L were associ-
ated with shorter survival (OS, NR vs. 57 months, P = 0.001; PFS, 66 vs. 47 months, P = 0.018;
Fig 4C). Moreover, in patients that experienced a partial response, an absolute involved-sHLC
value5 g/L was associated with a worse prognosis (PFS, NR vs. 28 months, P = 0.016) (Fig
4D). We also observed that patients with involved-sHLC values5 g/L after treatment had a
higher level of bone marrow infiltration, as shown with cytology (9.18% vs. 2.27%; t-test,
P = 0.023) and immunophenotyping (1.7% vs. 0.30%; t-test, P = 0.027).
The suppression of uninvolved-HLC pairs (defined as an abundance less than 50% of the
lower concentration in the HLC pair) after treatment did not appear to have a prognostic
impact in our series (OS, P = 0.466; PFS, P = 0.381).
Discussion
Traditionally, the monoclonal component in serum is quantified and characterized with sPE
and immunofixation, respectively. The main limitations of these techniques are the lack of
standardization, limited sensitivity, and to a certain extent, subjectivity. sFLC and sHLC assays
complement and can increase the diagnostic sensitivity of serum studies in MM.
In addition to the diagnostic utility of the quantitative sFLC assay [3], an abnormal sFLCr
or a high content of the involved-sFLC at the treatment response assessment may also be
Table 2. Relationship between accepted response categories and sFLCr normalization.
No. of patients sFLCr status
Category of response Normal (%) Abnormal (%)
CR 130 84 (65) 46 (35)
VGPR 24 13 (54) 11 (46)
PR 125 48 (38) 77 (62)
SD 22 2 (9) 20 (91)
PD 8 1 (12) 7 (88)
Total 309 148 161
sFLCr normalization was related to a better response (Χ2, P<0.0001); however, an analysis of the sFLCr
normalization status in each response category showed that a normalized sFLCr did not affect survival.
CR: complete response; VGPR: very good partial response; PR: partial response; SD: stable disease; PD: progressive
disease
https://doi.org/10.1371/journal.pone.0203392.t002
Utility of sFLCr and sHLCr in multiplemyeloma
PLOSONE | https://doi.org/10.1371/journal.pone.0203392 September 7, 2018 7 / 14
prognostic of MM [3,12]. Moreover, the involved-sFLC concentration also reflects the disease
course in the majority of patients. In our series, at the time of diagnosis, HA-sFLCrs (<0.03 or
>32) [9] were not associated with differences in prognosis. This finding could be due to the
high efficacy of the drugs employed in our clinical trials, which included both bortezomib and
immunomodulatory drugs (IMiDe). In this context, classic strategies for evaluating the
response have prognostic relevance, and achieving a CR is the main objective for improving
Fig 3. Absolute values of monoclonal proteins (MPs) measured with serum protein electrophoresis (sPE) vs. absolute values of the involved heavy-light
chains (isHLC). Correlation analysis shows agreement between the absolute values of IgA (blue, r = 0.65 and IgG (grey, r = 0.71) MPs and isHLC measurements.
https://doi.org/10.1371/journal.pone.0203392.g003
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survival. In the present study, among patients that achieved CR, the median PFS was 60.7
months and the median OS was NR (P<0.0001).
In the entire series of patients, regardless of the response achieved, sFLCr normalization
was correlated with a better response (Χ2, P<0.0001). As expected, a normal sFLCr was corre-
lated with better survival (OS, P = 0.025; PFS, P = 0.016). However, as we reported previously
[15], sFLC normalization in patients that achieved CR did not necessarily indicate a higher
quality response, at least from the point of view of clinical significance. Remarkably, we
observed that the presence of a very abnormal absolute involved-sFLC value100 mg/L after
treatment (median OS, NR vs. 58 months, P = 0.03; median PFS, 48 vs. 33 months, P = 0.007)
occurred more commonly in patients with a partial response. The prognosis of patients in par-
tial response with high levels of involved-sFLC was similar to that of patients with stable
Fig 4. Progression-free survival (PFS) relationships to the absolute value of involved serum heavy-light chain (isHLC) and the ratio of highly abnormal sHLC
(HA-sHLCr). (A) PFS among patients with absolute values of isHLC<30 g/L (blue, median PFS: 39 mo), 30–50 g/L (green, median PFS: 26 mo), or>50 g/L (red,
median PFS: 35 mo). (B) PFS among patients with HA-sHLCr (<0.29 or>73, red; median PFS: 29 mo) vs. those with normal sHLCr (0.29–73, blue; median PFS: 36
mo). (C) PFS among patients with after-treatment absolute values of isHLC<5 g/L (blue, median PFS: 66 mo) vs.5 g/L (red, median PFS: 47 mo), regardless of the
response achieved. (D) PFS among patients that achieved partial response (PR) after treatment with absolute values of isHLC<5 g/L (blue, median PFS: Non reached
(NR) vs.5 g/L red, median PFS: 28 mo).
https://doi.org/10.1371/journal.pone.0203392.g004
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disease; thus, these patients might benefit from additional treatment. These findings indicated
that the sFLC could be a useful tool for monitoring disease in this scenario.
The greatest value of the recently developed sHLC assays is their ability to differentiate
between complex immunoglobulin isotypes; i.e., the heavy chain bound to either a κ or λ light
chain (Igκ and Igλ). This assay facilitates the determination of Ig-κ/λ ratios (e.g., the IgG-κ/
IgG-λ ratio). The strong correlations we found between involved-sHLC values and the MP
determined with sPE were highly relevant, both at diagnosis and at the treatment response
assessment (P<0.01; Pearson’s r = 0.692). This study did not investigate the correlation
between sHLC quantification and nephelometry, due to limitations in the nephelometry mea-
surements. When identifying the MP, we could only a quantify the total immunoglobulin con-
tent with nephelometry.
In the present study, we observed that HA-sHLCr values (<0.29 or>73) at the time of diag-
nosis were associated with a shorter PFS, even in the multivariable analysis (S2 Table). Of note,
MP quantifications with sPE could not confirm an association between MP values and prog-
nosis in a multivariable analysis, consistent with a previous study [23]. However, in our series,
the absolute values of involved-sHLC (for IgG and IgA) showed a linear correlation with abso-
lute values of MP, measured with sPE. This result suggested that sHLC values may represent
the tumor burden better than other tests for measuring MPs. Indeed, these measurements
could be highly applicable in certain cases, according to a recent report by Michallet et al [24].
When we investigated IgG and IgA isotypes separately, we found a higher correlation
between immunoglobulin levels and prognosis in the IgG group than in the IgA group. The
discrepancies that we observed between immunoglobulins quantified with sHLC and sPE
could be due to co-migration with other proteins in the β region. This factor could have led to
inaccurate results, due to the tendency to overestimate with sPE and the possibility of subjec-
tivity in certain cases.
As described above, in our series, at the time of diagnosis, polyclonal immunosuppression
(in the form of systemic immunoparesis, immunoparesis of the same class, or both) had no
impact on survival, even when we studied values below 50% of the lowest range. Other studies
have investigated the role of sHLC assays in MGUS. For example, Katzmann et al. [6] used
sHLC assays to measure monoclonal and polyclonal sHLCs separately as a novel means of
investigating heavy chain isotype-specific immunoparesis as a predictor of MGUS progression.
They found that IgG plasma cell clones suppressed polyclonal IgG synthesis more efficiently
than IgA and IgM secretion. More importantly, suppression of an HLC pair (i.e., suppression
of IgG-κ in IgG-λ MGUS) was an independent predictor of progression to MM. In our study
of patients with symptomatic MM, we found no association between the risk of progression
and polyclonal immunosuppression.
When we used sHLC to evaluate the treatment response, measured in terms of sHLCr nor-
malization, we found no differences in survival between responders and non-responders.
However, the availability of samples for these measurements was insufficient to allow robust
conclusions. In our series, an absolute involved-sHLC value5 g/L implied worse survival,
and it was related to a lower level of response. Additionally, among patients with a partial
response, an absolute involved-sHLC value5 g/L could identify patients at higher risk of pro-
gression. These results suggested that sHLC might be useful for monitoring disease, particu-
larly among patients that are difficult to follow with classical techniques (e.g., when IgA or
IgG MM migrates in the β region of the proteinogram). Moreover, we found that absolute
involved-sHLC values5 g/L were related to higher levels of plasma cell infiltration, based on
cytology (9.18% vs. 2.27%; t-test, P = 0.023) and immunophenotyping (1.7% vs. 0.30%; t-test,
P = 0.027).
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In conclusion, our results suggested that HA-sHLCr values (<0.29 or >73) detected at the
time of diagnosis might indicate an increased risk of progression; moreover, HA-sHLCr values
might offer better prognostic value than sFLC assays in evaluating patients with MM. After
treatment, absolute involved-sHLC values5 g/L could identify patients with poor survival. In
our series, the classic CR definition, based on negative immunofixation and bone marrow
infiltration <5%, remained a good parameter for assessing treatment response. However, our
results showed that, among patients with a poor treatment response, evaluating the response
in terms of involved-sFLC and involved-sHLC levels could identify patients with MM that
have a poor prognosis. Therefore, these assays are complementary to other techniques for eval-
uating MP, such as sPE or immunofixation, in cases that are challenging to follow-up (e.g.,
when IgA MM and IgG MM co-migrate with other proteins in the β region of the proteino-
gram or in cases of oligosecretory MM). One important consideration is that all of these stud-
ies were performed with participants of clinical trials that did not have renal impairment. In
particular, renal impairment could interfere with sFLC measurements; therefore, sFLC mea-
surements should be carefully evaluated in real-world practice.
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(TIF)
S2 Fig. Overall survival (PFS) relationships to the absolute value of involved serum heavy-
light chain (isHLC) and the ratio of highly abnormal sHLC (HA-sHLCr). (Figure A in S2
Fig) OS among patients with absolute values of isHLC <30 g/L (blue, median OS: 67 mo), 30–
50 g/L (green, median OS: 57 mo), or >50 g/L (red, median OS: 51 mo). (Figure B in S2 Fig)
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normal sHLCr (0.29–73, blue; median not reached(NR)). (Figure C in S2 Fig) OS among
patients with after-treatment absolute values of isHLC <5 g/L (blue, median OS NR) vs.5 g/
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(TIF)
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